CNSP
Cns Pharmaceuticals Inc

7,874
Loading...
Loading...
News
all
press releases
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved
The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.
Stocktwits·5mo ago
News Placeholder
More News
News Placeholder
Why CNS Pharmaceuticals (CNSP) Stock Is Up 86%
CNS Pharmaceuticals shares are trading higher by 76% Wednesday morning. The stock faces potential delisting for not meeting Nasdaq's $1.00 bid price. read more...
Benzinga·1y ago
News Placeholder
What's Going On With CNS Pharmaceuticals Stock Tuesday?
CNS Pharmaceuticals entered into a exclusive license agreement with Cortice Biosciences. read more...
Benzinga·1y ago
News Placeholder
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin...
Accesswire·2y ago
News Placeholder
CNS Pharmaceuticals to Present at Two Investor Conferences in April
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...
Accesswire·2y ago
News Placeholder
CNS Pharmaceuticals prices $4M public offering
CNS Pharmaceuticals prices $4M public offering...
SeekingAlpha.com: All News·2y ago
News Placeholder
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...
Accesswire·2y ago
News Placeholder
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and...
Accesswire·2y ago
News Placeholder
CNS Pharmaceuticals completes planned enrollment in study of berubicin in GBM
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...
Accesswire·2y ago

Latest CNSP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.